The 2-year local recurrence-free survival (LRFS) improved from 76.0% without adjuvant RT to 87.1% with it. Disease-free (DFS) ...

In a recent conversation with CURE, Hensley discussed the current treatment landscape of non-muscle-invasive bladder cancer, ...

Frank Garred, 77, completed TAR-200 treatment for recurrent bladder cancer, describing it as manageable with minimal side ...

Adjuvant radiotherapy could substantially reduce risk for locoregional recurrence for patients with advanced muscle-invasive ...

(Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the ...

Discover a study exploring how bladder cancer organoids advance personalised drug testing, reveal tumour heterogeneity, and ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, ...

The ESMO 2025 Congress will highlight late-breaking abstracts on RCC and bladder cancer, focusing on immune checkpoint ...

MIBC requires a multimodal treatment approach, with radical cystectomy as the gold standard and bladder-sparing options for select patients. Adjuvant immunotherapies, such as nivolumab and ...

NEW HAVEN, Conn. (WTNH) — The FDA recently approved the first breakthrough treatment for bladder cancer in 40 years. It comes at a time when Coach Prime – Deion Sanders – is sharing his bladder cancer ...

A groundbreaking Indian study, the BART trial, highlights that radiation therapy post-surgery safely reduces pelvic relapse ...

Immunocompromised patients with bladder cancer who undergo TURBT followed by BCG immunotherapy have worse survival outcomes compared to non-immunocompromised patients, a study suggests.